Xaira's core generative AI platform for de novo design of protein and antibody therapeutics. Uses RFdiffusion and RFantibody models to create drug-like molecules targeting molecules historically considered undruggable.
Active development since 2024. Pipeline programs in preclinical development.
Updated 23 Apr 2024Checked 10 Oct0 updates this week
RFdiffusion and RFantibody design novel molecules from scratch.
AI-driven target selection against historically undruggable mechanisms.
Robot arms synthesize and test designs in parallel at scale.
| Spec | X-Design |
|---|---|
| Founding round capital | $1 billion+R (reported) |
| Core generative models | RFdiffusion (proteins), RFantibody (antibodies)R (reported) |
R reported by the company
Xaira Therapeutics
AI drug discovery, generative proteins, antibody design, therapeutics
South San Francisco AI drug-discovery startup founded 2023 by Marc Tessier-Lavigne and David Baker (UW protein design). $1B+ funding from ARCH, Foresite. Builds generative AI for protein and antibody design against hard-to-drug targets.
